Investor Alert: Robbins LLP Informs Investors that a Class Action Lawsuit Has Been Filed Against Semler Scientific, Inc.

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for failing to disclose an investigation by the U.S. Department of Justice regarding potential violations of the False Claims Act [1][2]. Allegations - The lawsuit alleges that Semler Scientific did not disclose a material investigation by the DOJ into possible violations of the False Claims Act during the class period from March 10, 2021, to April 15, 2025 [2]. - On February 28, 2025, Semler Scientific revealed it had received an initial civil investigative demand from the DOJ in July 2017, investigating whether the company violated the False Claims Act by marketing certain tests as reimbursable by Medicare [3]. - Following unsuccessful settlement discussions with the DOJ on February 11, 2025, the company faced a risk of a civil lawsuit, leading to a stock price drop of $4.03, or 9.38%, closing at $38.89 on March 3, 2025 [3]. Settlement and Financial Impact - On April 15, 2025, Semler Scientific reported to the SEC that it had reached a settlement agreement with the DOJ for $29.75 million, excluding attorney fees, but noted that further payments might be necessary and the risk of a DOJ lawsuit still exists [4]. - Following the settlement announcement, Semler Scientific's stock price fell by $3.40 per share, or 9.88%, closing at $31.00 on April 16, 2025 [4].